Format

Send to

Choose Destination
See comment in PubMed Commons below
Urol Oncol. 2007 Sep-Oct;25(5):420-32.

Targeted therapies for kidney cancer in urologic practice.

Author information

1
Department of Medical Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA 19111, USA.

Abstract

Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies with nearly half of all patients presenting with locally advanced or metastatic disease. Systemic treatments such as chemo- or immunotherapy have historically been associated with overall response rates of 5-15% with very few durable responses. The basis of newly approved, more effective targeted therapies for metastatic RCC are based on a fundamental knowledge of the molecular mechanisms that give rise to RCC. We review the clinical data for targeted therapies in RCC and discuss the pertinent biology, side effects, and targets important to the practicing clinician.

PMID:
17826664
DOI:
10.1016/j.urolonc.2007.05.009
[Indexed for MEDLINE]

Publication type, MeSH terms, Substances

Publication type

MeSH terms

Substances

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center